CLINTON BYBEE
CIK 1219043 · last filed 2022-08-16
CLINTON BYBEE is a corporate insider who has filed 39 SEC Form 4 insider transactions across 16 companies since 2013. The most recent filing, for VIR, was dated Aug 16, 2022. Across all open-market trades the lifetime net is +$60.8M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $458.7M across reported positions. 113 SEC filings were submitted jointly with KEITH CRANDELL.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$458.72M
16
39
$60.75M
Filer Profile
SUITE 1025
CHICAGO, IL 60631
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VIR | 10%+ Owner | 208,852 | $10.62 | $2.22M | $0 | 2 | 2022-08-16 |
| BEAM | 10%+ Owner | 2,949,630 | $23.99 | $70.76M | $0 | 1 | 2021-07-02 |
| Karuna Therapeutics, Inc. (KRTX) Delisted | 10%+ Owner | 1,532,049 | $329.83 | $505.32M | $22.40M | 3 | 2021-01-12 |
| PI | Director | 17,125 | $176.82 | $3.03M | $97.7K | 14 | 2020-10-23 |
| Metacrine, Inc. (MTCR) Delisted | 10%+ Owner | 158,734 | $0.49 | $78.6K | $20.93M | 1 | 2020-09-22 |
| DNLI | 10%+ Owner | 10,668,749 | $21.09 | $225.00M | $0 | 1 | 2019-08-12 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | 10%+ Owner | 430,205 | $0.00 | $172 | -$2.94M | 1 | 2019-07-17 |
| Unity Biotechnology, Inc. (UBX) Delisted | 10%+ Owner | 629,860 | $0.20 | $126.0K | $0 | 1 | 2018-05-07 |
| Sienna Biopharmaceuticals, Inc. (SNNA) Delisted | 10%+ Owner | 2,750,575 | — | — | $0 | 1 | 2017-08-01 |
| XCOM | Director | 1,885,090 | $28.61 | $53.93M | $7.50M | 5 | 2016-10-13 |
| VBI VACCINES INC. (VBIV) Delisted | 10%+ Owner | 134,928 | $0.07 | $8.8K | $0 | 1 | 2015-08-17 |
| PULM | 10%+ Owner | — | $1.41 | — | $0 | 1 | 2015-06-25 |
| Sage Therapeutics, Inc. (SAGE) Delisted | 10%+ Owner | 2,124,699 | $8.68 | $18.44M | $0 | 2 | 2015-06-22 |
| Bellerophon Therapeutics, Inc. (BLPH) Delisted | 10%+ Owner | 64,377 | $0.01 | $773 | $12.76M | 1 | 2015-02-23 |
| AGIO | 10%+ Owner | 3,088,590 | $33.60 | $103.78M | $0 | 2 | 2015-02-23 |
| Juno Therapeutics, Inc. (JUNO) Delisted | 10%+ Owner | 7,347,015 | — | — | $0 | 1 | 2014-12-23 |
Recent Filings
39 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-08-16 | VIR | Other (J) | −10,132,437 | $0 | EDGAR |
| 2021-07-06 | VIR | Other (J) | −27,766,116 | $0 | EDGAR |
| 2021-07-02 | BEAM | Other (J) | −3,135,584 | $0 | EDGAR |
| 2021-01-12 | Karuna Therapeutics, Inc. (KRTX) Delisted | Other (J) | −1,041,152 | $0 | EDGAR |
| 2020-11-16 | Karuna Therapeutics, Inc. (KRTX) Delisted | Other (J) | −1,041,152 | $0 | EDGAR |
| 2020-10-23 | PI | Exer (M) | +3,411 | $0 | EDGAR |
| 2020-09-22 | Metacrine, Inc. (MTCR) Delisted | Mixed | +20,583,521 | $20.93M | EDGAR |
| 2020-06-12 | PI | Grant (A) | — | $0 | EDGAR |
| 2019-11-19 | PI | Other (J) | −410,063 | $0 | EDGAR |
| 2019-10-24 | PI | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.